Cargando…
ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer
The mechanistic target of rapamycin (mTOR) serine/threonine kinase, a critical regulator of cell proliferation, is frequently deregulated in human cancer. Although rapamycin inhibits the two canonical mTOR complexes, mTORC1 and mTORC2, it often shows minimal benefit as an anticancer drug. This is ca...
Autores principales: | Harwood, Franklin C., Klein Geltink, Ramon I., O’Hara, Brendan P., Cardone, Monica, Janke, Laura, Finkelstein, David, Entin, Igor, Paul, Leena, Houghton, Peter J., Grosveld, Gerard C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156121/ https://www.ncbi.nlm.nih.gov/pubmed/30258985 http://dx.doi.org/10.1126/sciadv.aar3938 |
Ejemplares similares
-
Establishment of a transgenic mouse to model ETV7 expressing human tumors
por: Numata, Masashi, et al.
Publicado: (2018) -
Zebrafish etv7 regulates red blood cell development through the cholesterol synthesis pathway
por: Quintana, Anita M., et al.
Publicado: (2014) -
Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
por: Murray, James T., et al.
Publicado: (2018) -
Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor
por: Artoni, Filippo, et al.
Publicado: (2023) -
Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines
por: Lin, Hugo You-Hsien, et al.
Publicado: (2014)